Evaluation of the impact of dutasteride/tamsulosin combination therapy on libido in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH): A post hoc analysis of a prospective randomised placebo‐controlled study
| Autor: | Rosen, Raymond C., Roehrborn, Claus G., Manyak, Michael J., Palacios‐Moreno, Juan Manuel, Wilson, Timothy H., Lulic, Zrinka, Giuliano, Francois |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
Original Paper Urology Libido Prostatic Hyperplasia Dutasteride Middle Aged Combined Modality Therapy Double-Blind Method Erectile Dysfunction Lower Urinary Tract Symptoms Meta-Analysis as Topic Surveys and Questionnaires Adrenergic alpha-1 Receptor Antagonists Humans Urological Agents Drug Therapy Combination Prospective Studies Men's Health Aged Randomized Controlled Trials as Topic |
| Zdroj: | International Journal of Clinical Practice |
| ISSN: | 1742-1241 1368-5031 |
| Popis: | Summary Aims Five‐α reductase inhibitor (5ARI) therapy has been associated with sexual dysfunction in some patients. This study assessed the impact of a fixed‐dose combination of the 5ARI dutasteride 0.5 mg and the α1‐adrenoceptor antagonist tamsulosin 0.4 mg (DUT‐TAM FDC) on Men's Sexual Health Questionnaire (MSHQ) domain scores in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH). Methods This was a post hoc analysis of a double‐blind, randomised, placebo‐controlled, parallel‐group, multicentre study in sexually active patients, aged ≥50 years, with a confirmed clinical diagnosis of BPH. Sexual activity, sexual desire, and bother domain scores of the MSHQ were assessed at baseline and at Months 1, 3, 6, 9, and 12. Correlation between MSHQ sexual activity/desire scores and ejaculation, erection, and satisfaction domains at baseline was also evaluated. Results In the intent‐to‐treat population (N = 489), 243 and 246 patients were randomised to DUT‐TAM FDC and placebo groups, respectively. Compared with placebo, DUT‐TAM FDC therapy resulted in statistically significant reductions (worsening) from baseline in adjusted mean MSHQ sexual activity and bother domain scores at Months 1, 3, 6, 9, and 12 (all P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|